drug_type
RELEVANT_DRUG
intervention_type
Vaccine (adenoviral vector prime)
drug_description
KRAS-targeted adenoviral vector vaccine used as a prime to induce and expand KRAS-mutant–specific T cells.
nci_thesaurus_concept_id
C165514
nci_thesaurus_preferred_term
Neoantigen-based Therapeutic Cancer Vaccine GRT-C903
nci_thesaurus_definition
A cancer priming vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of neoantigen-based therapeutic cancer vaccine GRT-C903, followed by the boosting vaccine GRT-R904, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.
drug_category
GENE THERAPY
drug_class
Vaccine
drug_delivery_route
Intramuscular
drug_mechanism_of_action
A non-replicating adenoviral vector delivers genes encoding shared KRAS-mutant neoantigens to antigen-presenting cells, leading to intracellular expression and MHC I/II presentation of the neoantigen peptides. This primes and expands KRAS-mutant–specific CD8+ and CD4+ T cells, promoting cytotoxic T‑cell responses against KRAS‑mutant tumor cells (used as a prime prior to an mRNA boost).
drug_name
GRT-C903
nct_id_drug_ref
NCT06253520